ACE1831 not checked

Acepodia Biotech, Inc.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1/2 trial completes
Trials
1 active
2 in total
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“ACE1831 is allogeneic gamma delta T (gdT) cell therapy. Subjects will receive ACE1831 dose based on the assigned dose escalation cohort.”In the company’s words, NCT07061938 on ClinicalTrials.gov
Tested for
IgG4 Related Disease
Main trialPhase 1/2
“ACE1831 is an off-the-shelf, allogeneic gamma delta T (gdT) cell therapy derived from healthy donors, that is under investigation for the treatment in subjects with Immunoglobulin G4 Related Disease (IgG4-RD)”In the company’s words, NCT07061938 on ClinicalTrials.gov

Other drugs for IgG4 Related Disease

All 5 drugs for IgG4 Related Disease

Coming up1

Changes1

Last 90 days

Trials2

TrialPhaseCompletesWhat it tests
Phase 1/2Active, not recruiting 20 Sep 2029 Study to Assess Safety, Efficacy and Persistence of ACE1831, in Subjects With IgG4-Related Disease
Phase 1Completed 31 Mar 2026 ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow ACE1831

Following is part of Solo: you see every change to ACE1831 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in